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Abstract
Background:  Campylobacter  is a major cause of human disease worldwide and poultry are
identified as a significant source of this pathogen. Most disease in humans is associated with the
consumption of contaminated poultry or cross-contamination with other foods. The primary drugs
of choice for treatment of human campylobacteriosis include erythromycin and ciprofloxacin. In
this study, we investigated the prevalence of resistance to erythromycin and ciprofloxacin in
Campylobacter isolates recovered from turkey carcasses at two processing plants in the Upper
Midwest US. Further analysis of a subset of isolates was carried out to assess resistance and
genotype profiles.
Results: Campylobacter isolates from plant A (n = 439; including 196 C. coli and 217 C. jejuni) and
plant B (n = 362, including 281 C. coli and 62 C. jejuni) were tested for susceptibility to ciprofloxacin
and erythromycin using agar dilution. C. coli were more frequently resistant than C. jejuni in both
plants, including resistance to ciprofloxacin (28% of C. jejuni and 63% of C. coli, plant B; and 11% of
C. coli, plant A). Erythromycin resistance was low among C. jejuni (0% plant A and 0.3% plant B)
compared to C. coli (41%, plant A and 17%, plant B). One hundred resistant and susceptible isolates
were selected for additional antimicrobial susceptibility testing, restriction fragment length
polymorphism analysis of the flaA gene (fla typing), and pulsed-field gel electrophoresis (PFGE). Fla-
PFGE types obtained (n = 37) were associated with a specific plant with the exception of one type
that was isolated from both plants. C. coli isolates (n = 65) were grouped into 20 types, while C.
jejuni isolates (n = 35) were grouped into 17 types. Most isolates with identical fla-PFGE patterns
shared identical or very similar antimicrobial resistance profiles. PFGE alone and composite analysis
using fla-PFGE with resistance profiles separated C. jejuni and C. coli into distinct groups.
Conclusion:  Ciprofloxacin and erythromycin resistance in Campylobacter  recovered from
processed turkey occurred more frequently among C. coli than C. jejuni. Fla-PFGE types were
associated with a particular species, antimicrobial resistance profiles, and a specific plant. Molecular
subtyping in this study provided more information about the relationships among antimicrobial-
resistant Campylobacter at the processing level.
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Background
Campylobacter spp. are one of the major causes of human
gastroenteritis worldwide and are estimated to cause over
two million cases of illness annually in the U.S. [1].
Greater than 95% of human infections are due to C. jejuni
or C. coli [2]. Human disease is characterized by diarrhea,
fever, and abdominal cramping [3]. Campylobacteriosis is
most often associated with the handling and consump-
tion of raw or undercooked poultry [2-4].
In poultry, Campylobacter  is considered a commensal
organism [4]. When colonized poultry enter the process-
ing plant, contamination of the carcass and processed
product can result [4]. Turkey is an important reservoir of
Campylobacter; studies have reported prevalence rates of
65-95% in U.S. turkeys at production [5-7]. In a study
from our lab, the prevalence of Campylobacter was 34.9%
from two turkey processing plants [8], while at the retail
level, the organism has been detected in 1.0-15% of sam-
ples tested [9,10].
Human campylobacteriosis is generally self-limiting,
although in severe cases it requires antimicrobial therapy.
Erythromycin and ciprofloxacin are often the drugs of
choice [11]. Fluoroquinolones such as ciprofloxacin have
been used for first-line treatment of bacterial gastroenteri-
tis in the absence of a microbiological diagnosis [3]. How-
ever, an increase in fluoroquinolone-resistant
Campylobacter infections in humans has been documented
worldwide [12-14], and may be associated with fluoro-
quinolone use in food animals [12,15,16]. Although the
approval of enrofloxacin (a fluoroquinolone) for use in
poultry was withdrawn by the U.S. Food and Drug
Administration in 2005, it is possible that fluoroqui-
nolone-resistant  Campylobacter  will persist in poultry
flocks [17]. Macrolides such as erythromycin have been
the preferred treatment for Campylobacter  infections
[3,13]; however, increasing resistance to erythromycin
among Campylobacter has been documented, particularly
in C. coli [12,18-20]. The duration of illness, risk of inva-
sive illness, or poorer treatment response has been shown
to be greater for patients infected with quinolone- or mac-
rolide-resistant Campylobacter [16,21-23]; although Was-
senaar et al. [24] did not find these effects associated with
fluoroquinolone-resistant  Campylobacter  infections. In
Campylobacter, resistance to quinolones and macrolides is
primarily associated with mutations in the gyrA and 23S
rRNA genes, respectively [20,25]. The involvement of the
CmeABC multidrug efflux pump in resistance to both
classes of antimicrobials has also been recognized
[26,27].
Information about antimicrobial resistance of Campylo-
bacter at different levels of production is important for the
development of control strategies for this pathogen. In
addition, differentiation of antimicrobial-resistant strains
is necessary to investigate the epidemiology of resistance.
Restriction fragment length polymorphism (RFLP) analy-
sis of the flaA gene (fla typing) and pulsed-field gel elec-
trophoresis (PFGE) are two genotyping methods used to
successfully differentiate Campylobacter  strains [28,29].
This study was conducted to assess the ciprofloxacin and
erythromycin resistance in Campylobacter  isolated from
turkey at the processing level. Fla typing, PFGE, and anti-
microbial susceptibility testing were used to characterize a
subset of ciprofloxacin- and/or erythromycin-resistant
and susceptible Campylobacter isolates obtained from pre
and post chill turkey carcasses and chill water.
Results
Antimicrobial susceptibility testing
Figure 1A and 1B shows the MICs of 801 Campylobacter
isolates to ciprofloxacin and erythromycin. Few isolates
were co-resistant to both antimicrobials (2 from plant A
[0.45% of plant A isolates] and 9 from plant B [2.5% of
plant B isolates]). Resistant isolates were recovered from
carcasses at pre chill and post chill at both plants. No sig-
nificant difference (P > 0.01) was observed between the
number of ciprofloxacin-resistant or erythromycin-resist-
ant isolates obtained from either process stage at plant A
(Table 1).
Differences were observed in the frequency of resistance
among C. coli compared to C. jejuni (Table 2). C. coli were
more likely to be erythromycin-resistant compared to C.
jejuni (41% plant A and 17% plant B compared to 0.0%,
plant A and 0.3%, plant B) (P < 0.01). C. coli were also
more likely to be ciprofloxacin-resistant compared to C.
jejuni in both plant A (C. coli, 11%; C. jejuni, 0.0%) and
plant B (C. coli, 63%; C. jejuni, 28%) (P < 0.01).
Additional antimicrobial susceptibility testing conducted
on a subset of isolates selected for subtyping (n = 100)
found that isolates from plant A (n = 51; C. jejuni, 8; C.
coli, 43) were resistant to tetracycline (100%), nalidixic
acid (49%; C. jejuni, 2; C. coli, 23), kanamycin (41%; C.
jejuni, 0; C. coli, 21), and streptomycin (41%; C. jejuni, 0;
C. coli, 21), while those from plant B (n = 49; C. jejuni, 27;
C. coli, 22) were resistant to nalidixic acid (94%; C. jejuni,
24; C. coli, 22), tetracycline (86%; C. jejuni, 26; C. coli, 16),
kanamycin (20%; C. jejuni, 9; C. coli, 1) and streptomycin
(18%; C. jejuni, 0; C. coli, 9). Sixteen different drug resist-
ance profiles were identified, with most isolates display-
ing resistance to more than one agent (Figure 2). None of
the isolates were resistant to all six agents tested. The two
most prevalent multiple resistance profiles observed were
1) ciprofloxacin, nalidixic acid and tetracycline for 25 iso-
lates (most common profile among C. jejuni) and 2) cip-
rofloxacin, nalidixic acid, kanamycin and tetracycline for
25 isolates (most common profile among C. coli)BMC Microbiology 2009, 9:203 http://www.biomedcentral.com/1471-2180/9/203
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Fla typing and pulsed-field gel electrophoresis
All of the isolates examined (n = 100) tested positive for
the flaA gene and 24 different fla types were observed.
Twenty-six PFGE types were observed. Fla  typing sepa-
rated the isolates into three major groups at 50% similar-
ity (data not shown), while PFGE separated them into two
major groups at 30% similarity (Figure 3). Similar fla
types were found in isolates originating from different
plants (types A, B, K, M and X). Two PFGE types were
detected in isolates from both plants (types 10 and 28).
Thirty-seven combined fla-PFGE types were obtained, 22
of which contained only single isolates (Figure 4). Plant A
isolates were grouped into 16 fla-PFGE types and plant B
isolates were grouped into 22 fla-PFGE types. Fla-PFGE
types were unique to a particular plant with the exception
of M10, which was isolated from both plants on different
days in the same month. M10 was also isolated once from
plant A in the previous month. In both plants, some iso-
lates obtained from different sampling stages (pre or post
chill) had identical fla-PFGE types.
Six fla types were observed for C. jejuni isolates, while
fourteen fla types were observed for C. coli isolates. Four
fla types within two of the three major clusters included
isolates of C. jejuni and C. coli (data not shown). Using
PFGE, C. jejuni isolates were divided into 13 PFGE types,
while C. coli were also divided into 13 PFGE types. The
two major clusters obtained with PFGE generally sepa-
rated the two species (Figure 3). Combined fla-PFGE types
were unique to a particular species. C. coli isolates (n = 65)
were grouped into 20 fla-PFGE types; three of these fla-
PFGE types (B4, L18, and P2) contained 62% of the total
C. coli isolates. C. jejuni isolates (n = 35) were grouped
into 17 fla-PFGE types; one fla-PFGE type (I3) contained
29% of the C. jejuni isolates, while the other fla-PFGE
types included no more than 3 C. jejuni isolates each.
Antimicrobial resistance profiles and combined fla-PFGE
types are shown in Figure 4. Thirty-seven isolates with the
same  fla-PFGE type had identical resistance profiles,
including fla-PFGE types J28, D28, I30, I3, P2, V2, R9, and
T6. Forty-one isolates with the same fla-PFGE type had
either identical resistance profiles or very similar resist-
ance profiles, including fla-PFGE types B4, U9, F22, L18,
M10, X11, and O20. Within some fla-PFGE types, the
MICs for the antimicrobials varied, generally between one
to four dilutions (data not shown). On occasion, different
fla-PFGE types from the same plant had identical antimi-
crobial resistance profiles (Figure 4). For example, types
A14 and J28 from plant B were both resistant to cipro-
floxacin, nalidixic acid, and tetracycline.
Composite analysis (Figure 4) using fla typing, PFGE, and
antimicrobial resistance profiles separated the isolates
into 30 distinct types. At 43% similarity, three major clus-
ters (I, II, and III) were evident. One isolate was not clus-
tered into any of these three groups. The majority of
isolates in group II were C. coli, while all of the isolates in
groups I and III were C. coli and C. jejuni, respectively.
The numerical index of discrimination (D) was used to
evaluate the results of fla typing, PFGE, and antimicrobial
resistance profiling. The discrimination index was highest
for fla-PFGE analysis (D = 0.9321) followed by PFGE (D =
0.9147), composite data (all three methods, D = 0.9137),
fla typing (D = 0.9119), and antimicrobial resistance pro-
filing (D = 0.8430).
Discussion
Campylobacter isolates from two turkey processing plants
in the upper Midwest were examined for susceptibility to
ciprofloxacin and erythromycin, antimicrobial agents
Antimicrobial susceptibility profiles of Campylobacter isolates  (n = 801) Figure 1
Antimicrobial susceptibility profiles of Campylobacter 
isolates (n = 801). Isolates from plant A (n = 439; open 
bars) and plant B (n = 362; black bars) were tested for anti-
microbial susceptibility using agar dilution. A. The frequency 
of MICs obtained for ciprofloxacin. The arrow denotes the 
breakpoint of ≥ 4 μg/ml. B. The frequency of MICs obtained 
for erythromycin. The arrow denotes the breakpoint of ≥ 32 
μg/ml.
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used for the treatment of human campylobacteriosis.
Although co-resistance to both antimicrobials was low,
resistance was detected and differences were observed in
the frequency of resistance in relation to species. C. coli
from plant A (41%) and plant B (17%) were more likely
to be erythromycin-resistantcompared to C. jejuni (plant
A, 0.0%; plant B, 0.3%) (P < 0.01). Similarly, other studies
on Campylobacter isolated from poultry have reported that
erythromycin resistance occurs more frequently in C. coli
than C. jejuni [6,9,18,30-32]. The occurrence of erythro-
mycin resistance among C. coli isolated from the process-
ing environment in this study (41%, plant A and 17%,
plant B) was greater in comparison to 11.8% and 12.5%
for C. coli from retail turkey in the U.S. [9] and Germany
[33], respectively. Erythromycin resistance among C.
jejuni in this study was very low, similar to the aforemen-
tioned reports on retail turkey where resistance was 0% for
C. jejuni in both countries [9,33]. In contrast, 6.4% of C.
jejuni obtained from turkeys at a Belgian slaughterhouse
were resistant [32].
In this study, the frequency of ciprofloxacin resistance was
also found to be higher in C. coli (plant A, 11%; plant B,
63%) compared to C. jejuni (plant A, 0.0%; plant B, 28%)
(P < 0.01). Others have reported a higher occurrence of
fluoroquinolone resistance in C. coli compared to C. jejuni
as well [6,19,30,34]. In comparison to previous studies
conducted at different parts of the production system, cip-
rofloxacin resistance at plant B (28% in C. jejuni and 63%
in C. coli) was similar to U.S. turkeys at the farm level
[6,35], Belgian turkey at slaughter [32] and retail turkey in
Germany [33].
Resistance to multiple antimicrobial agents was observed
in most of the Campylobacter isolates selected for molecu-
lar profiling (Figures 2 and 4). Most isolates were resistant
to 3 or 4 agents. The most frequent resistance profile
observed among C. jejuni isolates was to ciprofloxacin,
nalidixic acid, and tetracycline. This profile was also
reported as the most common multidrug resistance pat-
tern for human Campylobacter isolates received through
NARMS from 1997-2001 [13]. In this study, the most
common multiple resistance pattern among C. coli iso-
lated from turkey was resistance to ciprofloxacin, nalidixic
acid, kanamycin, and tetracycline. These findings differ
from reports by Lee et al. [36] and Luangtongkum et al.
Table 1: Antimicrobial resistance and sampling stage distribution of Campylobacter isolates (n = 801).
Plant A Plant B
Sampling Stage Total Isolates Ciprofloxacin 
Resistance
Erythromycin 
Resistance
Total Isolates Ciprofloxacin 
Resistance
Erythromycin 
Resistance
Pre Chill 225a (51)b 7c (3.1)d 46c (20)d 242a (67)b 99c (41)d 6c (2.5)d
Post Chill 209 (48) 16 (7.7) 35 (17) 119 (33) 37 (31) 4 (3.4)
Chill Water 5 (1.1) 1 (20) 1 (20) 1 (0.3) 1 (100) 0 (0)
Total 439 24c (5.5)e 82c (19)e 362 137c (38)e 10c (2.8)e
aNumber of total isolates tested.
bPercentage of total isolates tested.
cNumber of isolates resistant.
dPercentage of isolates resistant among total tested for that stage.
ePercentage of isolates resistant among total tested for that plant.
Table 2: Ciprofloxacin and erythromycin resistance of Campylobacter spp. from two commercial turkey processing plants.
Plant A Plant B
Species No. (%) No. (%) resistant to 
ciprofloxacin
No. (%) resistant to 
erythromycin
No. (%) No. (%) resistant to 
ciprofloxacin
No. (%) resistant to 
erythromycin
C. jejuni 217a (49)b 0c (0.0)d 0c (0.0)d 281a (78)b 80c (28)d 1c (0.3)d
C. coli 196 (45) 22 (11) 81 (41) 62 (17) 39 (63) 9 (17)
C. fetus 1 (0.2) 0 (0.0) 0 (0.0) 3 (0.8) 3 (100) 0 (0.0)
C. lari 7 (1.6) 2 (29) 1 (14) 0 (0.0) n/a n/a
C. upsaliensis 3 (0.7) 0 (0.0) 0 (7.0) 0 (0.0) n/a n/a
Campylobacter spp. 15 (3.4) 0 (0.0) 0 (0.0) 16 (4.4) 15 (94) 0 (0)
Total 439 24c (5.5)e 82c (19)e 362 137c (38)e 10c (2.8)e
aNumber of total isolates tested.
bPercentage of total isolates tested.
cNumber of isolates resistant.
dPercentage of isolates resistant among total tested for that species.
ePercentage of isolates resistant among total tested for that plant.BMC Microbiology 2009, 9:203 http://www.biomedcentral.com/1471-2180/9/203
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[6], where resistance profiles of ciprofloxacin, nalidixic
acid, erythromycin, streptomycin, kanamycin, and tetra-
cycline resistance predominated in C. coli from turkeys.
In addition to expanded antimicrobial resistance testing,
fla typing and PFGE were used to further characterize anti-
microbial-resistant C. jejuni and C. coli from processed
turkey. It was observed that most of the Campylobacter iso-
lates with identical fla-PFGE types had the same antimi-
crobial resistance profiles, a finding also noted by Ge et al.
using PFGE [30]; however, analysis of additional antimi-
crobial-sensitive strains would be indicated. For subtyp-
ing  C. jejuni and  C. coli in this study, the greatest
discrimination index was obtained using fla-PFGE
together. Similarly, Nayak et al. [35] found a combination
of subtyping methods for Campylobacter isolated from tur-
key farms had a greater discriminatory value than a single
method. In the current study, fla typing failed to distin-
guish completely between the two Campylobacter species,
a finding also noted by others [37-39]. In contrast, PFGE
showed greater discrimination in separating the two spe-
cies, which can be attributed to its ability to detect whole
genome restriction site polymorphisms [29]. In addition
to discriminatory value, other characteristics of these
molecular typing methods should be acknowledged,
which have been reviewed elsewhere [28,29,37,40,41].
Fla typing is a useful tool for subtyping campylobacters
[39,42], and has the advantages of being simple, quick,
and low cost [28,29,42]. Nayak et al. reported that fla typ-
ing was more suitable than PFGE for typing C. coli isolated
from turkey farms [35]. However, the potential for recom-
bination within the fla genes is a drawback of using fla
typing alone or for long-term studies [29,43]. For this rea-
son, and because fla typing is generally less discriminatory
than PFGE, it is recommended to use fla typing in con-
junction with other typing methods [29,41]. PFGE is
highly discriminatory and well-accepted for typing
campylobacters, although it is laborious and can be
expensive [29,37]. PFGE profiles may also be affected by
genetic instability in Campylobacter [28,29].
In this study, the genetic diversity of antimicrobial-resist-
ant strains varied between C. coli and C. jejuni. One fla-
PFGE type (I3) contained 29% of the C. jejuni isolates
while the remaining 16 fla-PFGE types contained one to
three isolates each. In contrast, most of the C. coli isolates
(62%) were grouped into only three fla-PFGE types, sug-
gesting less diversity among C. coli. Bae et al. [44] demon-
strated that PFGE types of antimicrobial-resistant C. coli
from cattle were less diverse than those of C. jejuni, and
Nayak et al. [35] reported a similar effect among antimi-
crobial-resistant C. coli and C. jejuni from turkey farms.
Wesley et al. [7] described the opposite case, that C. coli
from turkeys were more diverse than C. jejuni based on
PFGE, although antimicrobial resistance was not deter-
mined.
The Campylobacter isolates examined in this study origi-
nated from turkey carcasses at either the pre or post chill
stages of processing. The prevalence of ciprofloxacin or
erythromycin resistance was similar from either stage in
plant A. In contrast, Berrang et al. found that the numbers
of erythromycin-resistant C. jejuni on broiler carcasses
were reduced after chilling, and suggested further study to
determine whether this resistance influences the ability of
Campylobacter to endure immersion chilling [45]. In the
current study, several of the same fla-PFGE types were
recovered from both stages, indicating that some cipro-
floxacin- and/or erythromycin-resistant strains were
present beyond chilling. Information about antimicro-
bial-resistant Campylobacter on post-chill turkey product is
limited and further study is needed.
Most of the fla-PFGE types (36 of 37) in the current study
were unique to a particular plant. Similarly, Rasschaert et
al. [46] demonstrated that most fla-PFGE types obtained
from broilers at three processing plants were unique
within a particular plant. The two plants participating in
the current study were located approximately 150 miles
apart in different states and were not likely to receive tur-
keys from the same farms. Isolation of the same fla-PFGE
type (M10) from both plants may suggest a common
source of this type, and warrants further investigation.
However, it must be noted that the isolates subtyped for
this study comprised a small portion of the entire Campy-
lobacter collection (n = 801) tested, which may influence
the frequency of fla-PFGE types obtained and is a limita-
tion of our study.
Antimicrobial resistance profiles and frequency among  selected Campylobacter isolates (n = 100) Figure 2
Antimicrobial resistance profiles and frequency 
among selected Campylobacter isolates (n = 100). C. 
jejuni (n = 35; open bars) and C. coli (n = 65; black bars) iso-
lates were tested for antimicrobial resistance using agar dilu-
tion. Presence of a letter indicates resistance, with C = 
ciprofloxacin, N = nalidixic acid, E = erythromycin, S = strep-
tomycin, K = kanamycin, and T = tetracycline.
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Dendrogram of PFGE types for Campylobacter isolates (n = 100) Figure 3
Dendrogram of PFGE types for Campylobacter isolates (n = 100).
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Composite dendrogram for Campylobacter isolates (n = 100) based on fla typing, PFGE, and antimicrobial resistance Figure 4
Composite dendrogram for Campylobacter isolates (n = 100) based on fla typing, PFGE, and antimicrobial 
resistance. Presence of a colored square indicates resistance, with C = ciprofloxacin, N = nalidixic acid, E = erythromycin, S 
= streptomycin, K = kanamycin, and T = tetracycline.
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Clustering using PFGE alone or fla-PFGE in conjunction
with resistance profiles separated C. jejuni and C. coli into
different groups. The diversity of genetic profiles, in con-
junction with differences in resistance profiles by species,
further supports the importance of considering C. jejuni
and C. coli separately in epidemiological investigations
[7,30,47,48]. Although C. jejuni is implicated in most
campylobacteriosis cases, human illness attributed to C.
coli is also recognized [13,47,49,50]. C. coli is often asso-
ciated with pigs; but was prevalent in turkeys in our previ-
ous study [8] and those of others [7,51]. In Denmark,
poultry, but not pigs, were associated with human C. coli
infections [48].
Conclusion
This study found that ciprofloxacin and erythromycin
resistance was present in Campylobacter  recovered from
processed turkey in the Upper Midwest, and the preva-
lence differed significantly between C. jejuni and C. coli.
Resistance observed in these strains has the potential to
complicate the effectiveness of treatment for poultry-
acquired Campylobacter infections in humans should they
remain on the processed product. Molecular subtyping
using fla typing and PFGE provided additional informa-
tion on antimicrobial-resistant Campylobacter from proc-
essed turkey. Fla-PFGE types were relatively diverse and
associated with a specific plant and species. Some cipro-
floxacin and/or erythromycin resistant isolates with the
same fla-PFGE types were recovered from processing both
before and after chilling. Factors contributing to the
occurrence of antimicrobial-resistant Campylobacter  in
processed turkey warrant further investigation.
Methods
Campylobacter isolates
Campylobacter isolates in this study (n = 801, Table 2) were
obtained from two unrelated Midwestern processing
plants (A and B) prior to the FDA ban of enrofloxacin use
in poultry [8]. Plant A received turkeys from independent
producers belonging to a farmers' cooperative, while plant
B received turkeys from producers under contract with a
large turkey processing company. Isolates were recovered
and identified by Logue et al. as previously described [8].
Briefly, isolates were recovered from whole carcass swabs
collected from randomly selected carcasses at two points
on the processing line: pre chill and post chill, from plants
visited monthly over a period of 12 months [8]. Samples
of the chill water were also collected. Birds sampled on a
single day were usually from one supplier or farm.
Throughout all parts of the study, isolates were removed
from -80°C storage in Brucella broth (Becton Dickinson,
Cockeysville, Md.) with 20% glycerol and cultured onto
sheep blood agar (BBL Prepared Media Trypticase Soy
Agar II, 5% Sheep Blood; Becton Dickinson, Sparks, Md.).
All cultures were incubated in a microaerobic environ-
ment of approximately 14% CO2 and 6% O2 generated by
Pack-Micro Aero (Mitsubishi Gas Chemical, New York,
N.Y.).
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing on all isolates (n =
801) was conducted using the agar dilution method
[52,53] with testing ranges of 0.008-4 μg/ml for cipro-
floxacin (Serologicals Proteins, Kankakee, Ill.) and 0.06-
32 μg/ml for erythromycin (Sigma Chemical, St. Louis,
Mo.). C. jejuni ATCC #33560 was used as a quality control
strain [11,53]. Resistance breakpoints were ≥ 4 μg/ml for
ciprofloxacin and ≥ 32 μg/ml for erythromycin [54]. Iso-
lates (n = 241) with an MIC of > 4 μg/ml for ciprofloxacin
and/or an MIC of > 32 μg/ml for erythromycin were re-
tested with extended antimicrobial concentrations of 0.5-
32 μg/ml for ciprofloxacin and 2.0-128 μg/ml for erythro-
mycin.
One hundred isolates (n = 51, plant A and n = 49, plant
B) were selected for further characterization. A similar
number of isolates from each plant and processing stage
were included in the subset, comprised of 58 cipro-
floxacin-resistant isolates, 22 erythromycin-resistant iso-
lates, 10 co-resistant isolates, and 10 isolates sensitive to
these two antimicrobials. C. jejuni and C. coli species iden-
tification was confirmed using multiplex PCR as described
previously [55]. Testing for susceptibility against tetracy-
cline, streptomycin, kanamycin and nalidixic acid was
conducted using the agar dilution method [52,53]. The
test ranges used were 0.06-32 μg/ml for tetracycline
(Sigma), 0.125-64 μg/ml for streptomycin (Sigma) and
kanamycin (Amresco, Solon, Ohio), and 0.25-128 μg/ml
for nalidixic acid (Sigma). The quality control strain used
was C. jejuni ATCC #33560 [11,53]. For streptomycin and
kanamycin testing, Escherichia coli ATCC #25922 and C.
jejuni ATCC #33560 were included. Campylobacter isolates
were defined as resistant or sensitive based on breakpoints
of ≥ 16 μg/ml for tetracycline, ≥ 64 μg/ml for nalidixic
acid, and ≥ 64 μg/ml for streptomycin and kanamycin
[54,56].
Fla typing
Fla typing (n = 100) was carried out using the method of
Nachamkin et al. [57] with minor modifications. Whole
cell lysate [58] was used as the template. PCR amplifica-
tion was performed in a Mastercycler gradient 5331 ther-
mocycler (Eppendorf, Hamburg, Germany). C. jejuni
ATCC #700819 was used as the positive control, and ster-
ile water was substituted for the DNA template as the neg-
ative control. To confirm the presence of the 1.7 kb flaA
amplicon, 10 μl of the PCR product was subjected to gel
electrophoresis followed by ethidium bromide staining
and UV transillumination. DdeI (Promega, Madison,
Wis.) was used to digest 5 μl of the flaA PCR productBMC Microbiology 2009, 9:203 http://www.biomedcentral.com/1471-2180/9/203
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according to the manufacturer's instructions at 37°C for
12-16 h overnight. Digested samples were electro-
phoresed on a 2% agarose gel, followed by staining in 0.5
μg/ml ethidium bromide solution and UV transillumina-
tion. A 100 bp ladder (Promega) was used as a molecular
size standard.
Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) was performed
using the PulseNet method [59] with slight modifications.
Salmonella enterica serotype Braenderup H9812 (ATCC
#BAA-664) was used as the molecular weight size stand-
ard. Restriction digestion of each sample plug slice was
carried out in a 100 μl mixture containing 85 μl sterile
water, 10 μl 10× J buffer, 4 μl of 10 U/μl SmaI (Promega),
and 1 μl BSA at 25°C for 3 h. Electrophoresis was per-
formed using the Chef Mapper system (Bio-Rad, Hercules,
Calif.) and the following conditions: auto algorithm func-
tion (50 kb low molecular weight and 400 kb high molec-
ular weight), run time 18 h, initial switch time 6.76 s and
final switch time 38.35 s. Gels were stained with 1 μg/ml
ethidium bromide solution for 30 min, destained in 500
ml reagent grade water for 60-90 min with water changes
every 20 min, and viewed under UV transillumination.
Documentation and analysis of fla typing and PFGE 
patterns
Gels were photographed and recorded as digital TIFF
images using an Alpha-Innotech imager (Alpha Innotech,
San Leandro, Calif.). Images were analyzed with Finger-
printing II Informatix software (Version 3.0, Bio-Rad).
Band matching and cluster analysis was performed using
an unweighted pair group method with arithmetic aver-
ages (UPGMA) and the Dice coefficient with 1% optimi-
zation and tolerance levels. Based on the dendrogram
obtained from the cluster analysis, letters were assigned to
designate fla types and numbers were assigned to desig-
nate PFGE types. Isolates with > 90% similarity were
assigned to the same fla type or PFGE type. Composite
cluster analysis including fla typing, PFGE, and antimicro-
bial resistance testing data was performed using the Fin-
gerprinting II Informatix software. The composite
dendrogram was determined by UPGMA using the aver-
age from the experiment as a coefficient for similarity and
correction for internal weights.
Statistical analysis
The χ2 test was used to analyze the significance of the dif-
ference between ciprofloxacin and erythromycin resist-
ance rates, including C. jejuni compared to C. coli in each
plant, and pre chill compared to post chill in plant A. An
α of 0.01 was used for statistical significance.
The discriminatory ability of fla typing, PFGE, antimicro-
bial resistance profiling, and composite analysis was cal-
culated using the numerical index of discrimination (D)
according to the method of Hunter and Gaston [60]. The
discriminatory index represents the probability that two
unrelated strains sampled from the test population will be
placed into different typing groups [60].
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